MedTrace Logo

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

NCT06083454 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-03-13

No results posted yet for this study

Summary

This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab

Conditions

Interventions

DRUG

Durvalumab

Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate

DRUG

Pharmacological ascorbate

Given intravenously in combination with Durvalumab

PROCEDURE

Surgery (SOC)

Surgery SOC

Sponsors & Collaborators

  • William Zeitler

    lead OTHER

Principal Investigators

  • William Zeitler, MD, MPH · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2025-04-04
Completion
2026-01-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083454 on ClinicalTrials.gov